Guidelines Developed for Lymphangioleiomyomatosis

Share this content:
Guidelines Developed for Lymphangioleiomyomatosis
Guidelines Developed for Lymphangioleiomyomatosis

FRIDAY, Sept. 16, 2016 (HealthDay News) -- Evidence-based guidelines have been developed for the diagnosis and treatment of lymphangioleiomyomatosis (LAM). The clinical practice guidelines were published online Sept. 15 in the American Journal of Respiratory and Critical Care Medicine.

Francis X. McCormack, M.D., from the University of Cincinnati, and colleagues conducted systematic reviews of evidence relating to diagnosis and treatment of LAM. A multidisciplinary panel summarized and discussed the evidence. Recommendations were formulated, written, and graded.

The authors note that recommendations were formulated for or against each specific intervention after considering the estimated effects, balance of benefits and harms and burden of treatment, consequences of treatment, patient values and preferences, cost, and feasibility. Based on evidence of varying quality, treatment with sirolimus was recommended rather than observation for patients with LAM with abnormal/declining lung function; treatment with sirolimus was recommended before invasive management for selected patients with LAM with problematic chylous effusions. Based on low-quality evidence, doxycycline was not recommended as treatment for LAM. Hormonal therapy should not be used as a treatment for LAM. Vascular endothelial growth factor D testing is recommended for establishing the diagnosis of LAM before considering diagnostic lung biopsy.

"The guidelines cannot take into account all of the complexities that clinicians face when making treatment decisions for patients with a rare lung disease," a coauthor said in a statement.

Several authors disclosed financial ties to the pharmaceutical industry.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Bavencio for Merkel Cell Carcinoma

FDA Approves Bavencio for Merkel Cell Carcinoma

Drug targets the PD-1/PD-L1 pathway; first sanctioned treatment in the United States

Heterogeneous Association for Alcohol, CVD Presentation

Heterogeneous Association for Alcohol, CVD Presentation

Non-drinking linked to increased risks of unstable angina, MI, heart failure, ischemic stroke, PAD, AAA

Mobile App Cuts In-Person Visits After Breast Reconstruction

Mobile App Cuts In-Person Visits After Breast Reconstruction

Number of visits down, increase in e-mails to doctors for ambulatory patients undergoing breast recon

is free, fast, and customized just for you!

Already a member?

Sign In Now »